Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males

Clinical Therapeutics

Volumn 32, Issue 7, 2010, Pages 1396-1407

  Liu, Yan Mei ^a   Pu, Hua Hua ^a   Liu, Gang Yi ^a   Jia, Jing Ying ^a   Weng, Li Ping ^a   Xu, Rong Jing ^b   Li, Guo Xiu ^b   Wang, Wei ^a   Zhang, Meng Qi ^a   Lu, Chuan ^a   Yu, Chen ^a  

^a SHANGHAI XUHUI CENTRAL HOSPITAL   (China)

^b Shanghai Novartis Trading Ltd   (China)

Author keywords

Atorvastatin; Bioequivalence; Chinese; Liquid chromatography isotope dilution mass spectrometry (LC IDMS); Ortho hydroxy atorvastatin; Pharmacokinetic

Indexed keywords

ATORVASTATIN; DRUG METABOLITE; ORTHO HYDROXY ATORVASTATIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CROSS-OVER STUDIES; DRUGS, GENERIC; HALF-LIFE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRROLES; TABLETS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 77955251731     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.07.004     Document Type: Article

References (30)

1. Heinonen TM, Stein E, Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: Results of a randomized, double masked study. Clin Ther. 1996, 18:853-863.
2. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995, 15:678-9318.
3. Jones P, Kafonek S, Laurora I, Hunninghake D Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [published correction appears in Am J Cardiol. 1998;82:128]. Am J Cardiol. 1998, 81:582-587.
4. Guerin M, Egger P, Soudant C, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: Preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis. 2002, 163:287-296.
5. Black DM, Bakker-Arkema RG, Nawrocki JW An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med. 1998, 158:577-584.
6. Turner AM, Jowett NI The role of statin therapy in preventing recurrent stroke. Nurs Times. 2006, 102:25-26.
7. Lennernäs H Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003, 42:1141-1160.
8. Jacobsen W, Kuhn B, Soldner A, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000, 28:1369-1378.
9. Kantola T, Kivistö KT, Neuvonen PJ Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998, 64:58-65.
10. Bullen WW, Miller RA, Hayes RN Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma. J Am Soc Mass Spectrom. 1999, 10:55-66.
11. Nirogi RV, Kandikere VN, Shukla M, et al. Simultaneous quantification of atorvastatin and active metabo- lites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. Biomed Chromatogr. 2006, 20:924-936.
12. Bahrami G, Mohammadi B, Mirzaeei S, Kiani S Determination of atorvastatin in human serum by reversed-phase high-performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2005, 826:41-45.
13. Chung M, Calcagni A, Glue P, Bramson C Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol. 2006, 46:1030-1037.
14. Posvar EL, Radulovic LL, Cilla DD, et al. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol. 1996, 36:728-731.
15. Koytchev R, Ozalp Y, Erenmemisoglu A, et al. Bioequivalence study of atorvastatin tablets. Arzneimittelforschung. 2004, 54:573-577.
16. Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly October 2000, World Medical Association Declaration of Helsinki (WMA), Scotland, Edinburgh, Accessed January 25, 2008. http://www.wma.net/en/30publications/10policies/b3/index.html.
17. European Agency for the Evaluation of Medical Products (EMEA). InternationalConferenceon Harmonisation-World Health Organization. Guideline for Good Clinical Practice. ICH topic E6 2002, WHO, Geneva, Switzerland, Accessed January 25, 2008. http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf.
18. center for drug evaluation. Guideline for bioavailability and bioequivalence studies of generic drug products State Food and Drug Administration (SFDA), Accessed January 25, 2008. http://www.cde.org.cn/zdyz.do?method=largePage&id=2066.
19. Guidance for Industry. Bioanalytical method validation US Dept of Health and Human Services, US Food and Drug Administration (FDA)US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM)Center for Veterinary Medicine (CVM), Accessed January 25, 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
20. Chow SC, Liu JP Design and Analysis of Bioavailability and Bioequivalence Studies 2000, 1-30. Marcel Dekker, New York, NY. 2nd ed.
21. Liu JP, Chow SC Sample size determination for the two one-sided tests procedure in bioequivalence. J Pharmacokinet Biopharm. 1992, 20:101-104.
22. Schuirmann DJ A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987, 15:657-680.
23. Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations US Dept of Health and Human Services, US Food and Drug Administration (FDA)US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Accessed January 25, 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf.
24. Lilja JJ, Kivistö KT, Neuvonen PJ Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther. 1999, 66:118-127.
25. Mazzu AL, Lasseter KC, Shamblen EC, et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther. 2000, 68:391-400.
26. Lins RL, Matthys KE, Verpooten GA, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant. 2003, 18:967-976.
27. Valera HR, Ganguly B Study of plasma level of atorvastatin and its effect on lipid profile. Indian J Physiol Pharmacol. 2009, 53:73-82.
28. Kajinami K, Akao H, Polisecki E, Schaefer EJ Pharmacogenomics of statin responsiveness. Am J Cardiol. 2005, 96:65k-70k.
29. Kajinami K, Akao H, Polisecki E, Schaefer EJ Pharmacogenomics of statin responsiveness. Am J Cardiol. 2005, 96:34k-70k. discussion.
30. Whitfield LR, Stern RH, Sedman AJ, et al. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase. Eur J Drug Metab Pharmacokinet. 2000, 25:97-101.